GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Pparg | decreases expression | EXP | | 6480464 | CTD | Indomethacin results in decreased expression of PPARG mRNA | PMID:36868495 | Pparg | increases activity | EXP | | 6480464 | CTD | Indomethacin results in increased activity of PPARG protein | PMID:11755111 | Pparg | multiple interactions | EXP | | 6480464 | CTD | Indomethacin inhibits the reaction [rosiglitazone binds to and affects the activity of PPARG protein] | PMID:12897060 | Pparg | affects localization | ISO | PPARG (Homo sapiens) | 6480464 | CTD | Indomethacin affects the localization of PPARG protein | PMID:15899809 | Pparg | increases activity | ISO | PPARG (Homo sapiens) | 6480464 | CTD | Indomethacin analog results in increased activity of PPARG protein; Indomethacin results in increased activity of PPARG protein | PMID:12065695 PMID:12485869 PMID:12606626 PMID:15273253 PMID:15899809 PMID:17602619 | Pparg | increases activity | ISO | Pparg (Mus musculus) | 6480464 | CTD | Indomethacin results in increased activity of PPARG protein | PMID:11683414 | Pparg | increases expression | ISO | PPARG (Homo sapiens) | 6480464 | CTD | Indomethacin results in increased expression of PPARG mRNA; Indomethacin results in increased expression of PPARG protein | PMID:12483719 PMID:17341418 PMID:31916655 | Pparg | multiple interactions | ISO | PPARG (Homo sapiens) | 6480464 | CTD | 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Indomethacin results in increased activity of PPARG protein]; [Bismuth affects the susceptibility to [INS protein co-treated with Dexamethasone co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine]] which results in decreased expression of PPARG mRNA; [Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA; [Indomethacin co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Indomethacin co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG protein; [Indomethacin co-treated with juglone] results in increased expression of PPARG mRNA; [Indomethacin co-treated with juglone] results in increased expression of PPARG protein; [Indomethacin co-treated with MK-886] affects the localization of PPARG protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PPARG mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Indomethacin binds to and results in increased activity of PPARG protein; Indomethacin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of PPARG mRNA]; Indomethacin inhibits the reaction [Rosiglitazone binds to PPARG protein]; Indomethacin promotes the reaction [MK-886 results in increased activity of PPARG protein] | PMID:12485869 PMID:15899809 PMID:16407166 PMID:20206132 PMID:28628672 PMID:31916655 PMID:34560244 PMID:34575692 PMID:9013583 | Pparg | multiple interactions | ISO | Pparg (Mus musculus) | 6480464 | CTD | [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein] | PMID:30055130 PMID:33412187 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |